SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: muddphudd who wrote (420)5/3/1998 6:45:00 PM
From: dougjn  Read Replies (2) of 2135
 
Read the Sun NYTimes article. First I've heard of EntreMed. I'm surprised this thread has not been deluged with postings today.

Does anyone have a clear sense of what rights Enmd has in the angiostatin/endostatin experimental therapy? The Times says only that EntreMed is "a company in Rockville, Md., that was formed to make and market angiostatin, endostatin and other weaker drugs than can slow cancer growth."

It also says later on that "Dr. John Holaday, Entremed's president and chief executive, said his company was working with the Bristol-Myers Squibb Company to develop angiostatin and had not yet decided on a corporate partner to develop endostatin. The drugs are being made in genetically engineered yeast growing in 20-gallon vats."

That was it on Enmd.

Is Enmd just producing the stuff in small amounts for research (with Dr. Folkman, or Harvard, or no one having any patent rights), or does Enmd have patent or other rights to it, or the process of making it? Anyone know?

Doug
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News